Aoxiang Pharmaceutical (603229.SH): Partnered product Ruxolitinib Tablets obtains overseas marketing authorization

Zhitong Finance APP news, Aoxiang Pharmaceutical (603229.SH) announced that recently, the subsidiary of its partner STADA Arzneimittel AG (hereinafter referred to as "STADA"), Spirig HealthCare AG, received the marketing authorization for Ruxolitinib Tablets approved and issued by the Swiss Agency for Therapeutic Products.